Enanta Pharmaceuticals ENTA
NASDAQ ENTA
$14.08 +0.06 (+0.43%)
As of: Sep 4, 2026 · 3:59 PM EDT

Enanta Pharmaceuticals (ENTA) EBT Growth (1y) (2013 - 2026)

Analysis

Enanta Pharmaceuticals (ENTA) EBT Growth (1y) (2013 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 8.48%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 0.60%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 88.92%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 6.23%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 213.87%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 530.43%
8 Royalty Pharma 28.45 Bn 27.61 Bn - -12.04%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 96.45%
10 Enanta Pharmaceuticals 409.30 Mn 219.79 Mn - -6.80%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -6.80%
Mar 31, 2026 45.37%
Dec 31, 2025 47.53%
Sep 30, 2025 36.04%
Jun 30, 2025 20.94%
Mar 31, 2025 24.02%
Dec 31, 2024 33.27%
Sep 30, 2024 1.12%
Jun 30, 2024 33.84%
Mar 31, 2024 16.20%
Dec 31, 2023 -17.26%
Sep 30, 2023 -12.09%
Jun 30, 2023 -8.39%
Mar 31, 2023 -11.97%
Dec 31, 2022 3.75%
Sep 30, 2022 21.14%
Jun 30, 2022 3.77%
Mar 31, 2022 -15.22%
Dec 31, 2021 -159.43%
Sep 30, 2021 -79.21%